Abivax (ABVX) Total Current Liabilities (2021 - 2026)

Abivax's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $72.9 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 34.5% year-over-year to $72.9 million in Q1 2026; TTM through Mar 2026 was $72.9 million, a 34.5% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, down 27.89% from the prior year.
• Total Current Liabilities fell to $72.9 million in Q1 2026 per ABVX's latest filing, from $73.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $127.2 million in Q2 2025 and bottomed at $52.5 million in Q4 2022.
• The 5-year median for Total Current Liabilities is $92.1 million (2025), against an average of $90.4 million.
• Across the five-year window, Total Current Liabilities soared 85.85% in 2023 and slumped 34.5% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $52.5 million in 2022, then soared by 85.85% to $97.6 million in 2023, then grew by 2.94% to $100.4 million in 2024, then slipped by 26.97% to $73.4 million in 2025, then fell by 0.68% to $72.9 million in 2026.
• Per Business Quant, the three latest ABVX Total Current Liabilities figures stand at $72.9 million (Q1 2026), $73.4 million (Q4 2025), and $92.1 million (Q3 2025).